 Connection
Catherine Klein to Antineoplastic Agents
This is a "connection" page, showing publications Catherine Klein has written about Antineoplastic Agents.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.162 |
|
|
|
-
Klein CE, Tangen CM, Braun TJ, Hussain MH, Peereboom DM, Nichols CR, Rivkin SE, Dakhil SR, Crawford ED. SWOG-9510: evaluation of topotecan in hormone refractory prostate cancer: a Southwest Oncology Group study. Prostate. 2002 Sep 01; 52(4):264-8.
Score: 0.091
-
Kelly K, Kittelson J, Franklin WA, Kennedy TC, Klein CE, Keith RL, Dempsey EC, Lewis M, Jackson MK, Hirsch FR, Bunn PA, Miller YE. A randomized phase II chemoprevention trial of 13-CIS retinoic acid with or without alpha tocopherol or observation in subjects at high risk for lung cancer. Cancer Prev Res (Phila). 2009 May; 2(5):440-9.
Score: 0.036
-
Whitehead RP, Unger JM, Flaherty LE, Kraut EH, Mills GM, Klein CE, Chapman RA, Doolittle GC, Hammond N, Sondak VK. A phase II trial of pyrazine diazohydroxide in patients with disseminated malignant melanoma and no prior chemotherapy--Southwest Oncology Group study. Invest New Drugs. 2002 Feb; 20(1):105-11.
Score: 0.022
-
Fisher CM, Klein CE, Kondapalli LA, Elias AD, Borges VF. Management of young breast cancer patients with de novo genetic mutations. Oncology (Williston Park). 2014 Oct; 28(10):895-6.
Score: 0.013
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|